Close
Smartlab Europe
Achema middle east

Novartis AG recalls 4 over-the-counter drugs

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience

Novartis has entered into a licensing agreement with SciNeuro...

Bayer-Attralus Diagnostic Tracers Deal Expands Imaging Reach

In order to broaden its portfolio in imaging and...

UK Clinical Trial Regulatory Reforms Aim to Boost Research

A number of regulatory changes have been released by...
- Advertisement -

Novartis AG said Sunday it is voluntarily recalling some over-the-counter products in the U.S., including its Excedrin headache pills and NoDoz medication, because they may contain broken or stray tablets from other products.

The recall also affects its Bufferin and Gas-X Prevention brands.Novartis has temporarily suspended operations at the Lincoln, Neb., plant where the products were made, the company said in a statement.The move comes after consumer complaints “of chipped and broken pills and inconsistent bottle packaging line clearance practices possibly resulting in mixed tablets,” the company said. The over-the-counter medications were distributed throughout the U.S.

Julie Masow, a spokeswoman for the Basel, Switzerland-based company, said she didn’t immediately have a number for the amount of tablets and gel caps involved in the recall. She said there hadn’t been any reports of overdoses or allergic reactions from the stray material or broken and chipped medication. The Lincoln facility’s products account for less than 2 percent of Novartis Group sales, Novartis said. The drugmaker had sales of $50.6 billion in 2010.

The company said it was recalling all lots of bottles containing Excedrin and NoDoz with expiration dates of Dec. 20, 2014, or earlier, as well as Bufferin and Gas-X Prevention with throw-out dates of Dec. 20, 2013, or earlier.

 

Latest stories

Related stories

Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience

Novartis has entered into a licensing agreement with SciNeuro...

Bayer-Attralus Diagnostic Tracers Deal Expands Imaging Reach

In order to broaden its portfolio in imaging and...

UK Clinical Trial Regulatory Reforms Aim to Boost Research

A number of regulatory changes have been released by...

The Future of Vertigo Diagnostic and Treatment Options in 2026

Vertigo is an uncomfortable sensation in which you feel...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »